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Adverse outcomeUnivariate statistical analyses have limited strength when employed in low-dose toxicogenomic studies,
due to diminished magnitudes and frequencies of gene expression responses, compounded by high data
dimensionality. Analysis using co-regulated gene sets and a multivariate statistical test based upon ranks
of expression were explored as means to improve statistical conﬁdence and biological insight at low-
doses. Sixteen gene regulatory groups were selected in order to investigate murine hepatic gene expres-
sion changes following low-dose oral exposure to the beta-adrenergic agonist, isoproterenol (IPR). Gene
sets in this focussed analysis included well-deﬁned gene batteries and synexpression groups with co-reg-
ulated responses to toxin exposures and linkage of chronic responses to adverse outcomes. Signiﬁcant
changes of target gene expression within Nfkb, Stat3 and 50 terminal oligopryrimidine (50TOP) batteries,
as well as the acute phase and angiogenesis synexpression groups, were detected at IPR doses 100-fold
lower than doses producing signiﬁcant individual gene expression values. IPR-induced changes in these
target gene groups were conﬁrmed using a similar analysis of rat toxicogenomic data from published
IPR-induced cardiotoxicity studies. Cumulative expression differences within gene sets were useful as
aggregated metrics for benchmark dose calculations. The results supported the conclusion that toxicolog-
ically-relevant, co-regulated genes provide an effective means to reduce microarray dimensionality,
thereby providing substantial statistical and interpretive power for quantitative analysis of low-dose,
toxin-induced gene expression changes.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.Introduction
Toxicogenomic gene expression proﬁling has been explored as
an adjunct methodology for dose–response characterizations of
chemical toxicity, with the expectation that it could offer a means
to improve this core element of quantitative human health risk
assessment. An attractive feature of toxicogenomic proﬁling re-
sides in its potential for more extensive insights into toxicological
modes-of-action (MOA) as compared to traditional toxicological
endpoints. Also, gene expression changes are thought to be
potentially more sensitive measures of effects at early time points
and at lower doses than many apical toxicological measures. Suchexpectations have generally been met in a range of studies. Gene
expression biomarkers have been used to describe dose–response
characteristics resulting from the action of estrogen receptor
ligands (estrogen, and xenoestrogens bisphenol A and genistein)
(Naciff et al., 2005), and in comparing toxicity equivalence factors
(TEFs) for Ah-receptor agonists (TCDD, PCB126, TCDF) (Kopec
et al., 2010). Other studies have determined threshold doses for
MOA-related measures of gene expression in molecular pathways
perturbed by the toxin formaldehyde (Andersen et al., 2010), or
drugs such as peroxisome proliferator activated receptor agonist
fenoﬁbrate, histamine H1 receptor antagonist, methapyrilene
(Bercu et al., 2010), beta-adrenergic receptor agonist isoprotere-
nol (Zheng et al., 2011), as well as various tyrosine kinase inhib-
itors (Ji et al., 2009). Therefore, identiﬁcation of statistically
signiﬁcant thresholds of toxicological effect, afﬁrmed by toxicog-
enomic analyses, have offered opportunities to directly apply tox-
icogenomic information in assigning benchmark doses as points
of departure for calculating exposure levels that would impose
minimal excess risk for human health (Bercu et al., 2010; Thomas
et al., 2007, 2011).
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nomic data have primarily employed per gene analysis, using uni-
variate methods with appropriate false discovery corrections. The
power to detect individual, differentially expressed genes is dimin-
ished by the high dimensionality of the data sets, in which the vari-
ables (genes on the microarray) are very large compared to the
number observations (experimental samples). Proper experimen-
tal design (Wei et al., 2004), pre-processing, normalization and ﬁl-
tering (Bourgon et al., 2010; Hackstadt and Hess, 2009; McClintick
and Edenberg, 2006; Yauk et al., 2006) prior to statistical analysis
and/or using statistics that borrows strength across genes (Baldi
and Long, 2001; Cui et al., 2005; Jain et al., 2003; Smyth, 2004;
Tong and Wang, 2007; Wright and Simon, 2003)can increase the
ability to detect differentially expressed genes, while still control-
ling the false discovery rate.
Further gains in statistical sensitivity have been derived from
the knowledge that genes never act alone. The fact that genes
interact with each other and are normally expressed in function-
ally relevant patterns suggests that gene-expression data can be
stratiﬁed and clustered into relatively homogenous groups (Barry
et al., 2005; Leung and Cavalieri, 2003; Lu et al., 2005; Qin et al.,
2008; Tuglus and Van Der Laan, 2009). Genes within these groups
are often correlated and dimensionality reduction into groups of
biologically relevant genes may improve screening power while
minimizing information loss to detect meaningful genes and or
expression proﬁles (Lu et al., 2005; Qin et al., 2008). Gene sets,
either through pathways, or modules (Engreitz et al., 2010; Huang
et al., 2007; Rahnenführer et al., 2004; Segal et al., 2003b,c,a) are a
natural means to reduce the dimensionality of microarray data
while gaining increased interpretation (Alvo et al., 2010; Beltrame
et al., 2009; Pavlidis et al., 2002; Rahnenführer et al., 2004). Using
multivariate techniques to utilize the information hidden in gene
interactions can provide more powerful, biologically meaningful
and reproducible results (Beltrame et al., 2009; Maglietta et al.,
2010; Stiglic et al., 2010; Zhao et al., 2009) for ﬁnding subsets of
differentially expressed genes which may not be detectable when
using univariate approaches (Engreitz et al., 2010; Lu et al., 2005;
Szabo et al., 2003; Zahn et al., 2006; Mar et al., 2011).
Established gene batteries and synexpression groups are
known, a priori, as co-expressed gene sets controlled by speciﬁc
molecular mechanisms or more complex combinations of controls,
respectively. Dimensional reduction of toxicogenomic data into
these sets should provide a direct, mechanistic approach with high
statistical power to detect toxin-induced differential gene expres-
sion across exposure levels. Gene sets with direct relevance to tox-
icological effects include the single transcription-factor controlled
gene batteries that respond in major cellular stress response path-
ways, including responses to oxidative stress, heat shock, DNA
damage, hypoxia, unfolded protein accumulation in the endplas-
mic reticulum, metal stress, osmotic stress, and inducers of
inﬂammation (Jennings et al., 2013; Simmons et al., 2009). The
ligand-activated nuclear receptor/transcription factors control spe-
ciﬁc batteries of drug and xenobiotic metabolic enzymes, catalys-
ing detoxiﬁcation or toxic activation of xenobiotics as well as
conversion of endogenous substrates that may be important for
tissue homeostasis (Tirona and Kim, 2005; Woods et al., 2007).
Additionally, endocrine disrupting agents may perturb the func-
tioning of receptor/transcription factors for endocrine hormones,
thereby altering normal expression patterns of the respective tar-
get gene batteries (Tabb and Blumberg, 2006).
Synexpression groups are regulated by more complex, signal-
response pathways and are highly coordinately expressed (across
tissues, time, or conditions) under the control of common sets of
signals and second messengers, usually in order to achieve a bio-
logical outcome (Niehrs and Pollet, 1999). It is thought that genes
within these groups share compound cis- and trans-acting controlelements to achieve coordinated gene expression in response to
various signals (Davidson, 2010; Nachman and Regev, 2009).
Developmental programs rely on spatio-temporal synexpression
of gene groups while certain tissue and cellular activities such as
the co-ordination and execution of the cell cycle or production of
the acute-phase response of the liver (as two examples) are regu-
lated transcriptionally in response to diverse biological and meta-
bolic inputs, including stress and toxicity. Less deﬁned groupings
of genes discovered by clustering algorithms in genome-wide
RNA proﬁling experiments, often labelled as synexpression groups,
were not included in this analysis because in many cases there is
little evidence to deﬁne the underlying control mechanisms or tox-
icological signiﬁcance of the expression changes.
Post-transcriptional mechanisms may also deﬁne gene groups
with co-ordinated regulation in response to cellular stresses. Tran-
script levels are controlled at multiple post-transcriptional levels
by RNA-binding proteins and miRNAs (Keene, 2007) and at the
translational level (entry or exit from polysomes), which affects
transcript stability. For example, the latter mechanism is known
in mRNAs with 50 terminal oligopyrimidine (50TOP) sequence mo-
tifs, as a response to growth arrest (Balagopal and Parker, 2009;
Meyuhas, 2000).
Monitoring gene expression changes coordinated through de-
ﬁned molecular events in stress-response pathways could provide
an integrated measure of outcome due to effects of toxins on these
complex signalling/response networks. Secondly, such coordinated
changes give insights into resultant adaptive, maladaptive, or toxic
consequences for cellular and tissue function. This report demon-
strates a multivariate gene-set approach for statistical analysis of
experimental dose–response data obtained for a selected panel of
gene batteries and synexpression groups of toxicological concern.
The data are converted to aggregated gene-set responses and ap-
plied in a benchmark dose assessment.Materials and methods
Animal treatment and microarray analysis
Male B6C3F1 mice (age 27–35 days; Charles River Laboratories)
were housed in individual cages under a 12 h light/12 h dark light-
ing schedule and were acclimatized for 2 weeks prior to the start of
the study. Mice were randomly assigned to treatment and control
groups (ﬁve animals per group) and were given a single dose of
250, 50, 5 and 0.5 mg/kg/day IPR via oral gavage and sacriﬁced
8 h after exposure. The control group received equivalent volumes
of 0.9% saline. Liver was removed and total liver RNA was isolated
and used for the microarray hybridization on ToxArrayTM chip v 1.2
(containing 1624 genes, 4 replicate probes per gene). Arrays were
scanned on a ScanArray Express (Perkin Elmer Life Sciences, Wood-
bridge, ON, Canada). The images were quantiﬁed using ImaGene
5.6 (BioDiscovery, Los Angeles, CA), and median signal intensities
(not background subtracted) were used for analyses. The complete
microarray data are publicly available (Zheng et al., 2011) and via
http://www.ebi.ac.uk/arrayexpress/, accession number: E-MEXP-
2716.Composition of gene battteries and synexpression groups for analysis
We employed pre-determined, and experimentally annotated
gene sets assembled from several sources: (1) TfactS (Essaghir
et al., 2010), for Stat3, Nfkb, Upr, Srebp1, and Creb1; (2) Gene Ontol-
ogy classiﬁcations for the angiogenesis synexpression group (a
combination of GO: 0045765, regulation of angiogenesis, and GO:
0001525, angiogenesis), KEGG pathways for the PPAR gene battery;
and (4) published literature for the acute phase synexpression
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gene set for Upr was formed as a combination of Atf6, Atf4 and
Xbp1 gene batteries obtained from the TfactS database. Lists of
the genes present on ToxarrayTM and Affymetrix Rat Genome 230
2.0 microarray are provided in a Supplementary Table.
2.3. Statistical analyses
A reference design with the sample labelled in Cy5 and the ref-
erence labelled in Cy3 was used to analyze the data. All pre-
processing of the data was conducted using R and the signal
intensities were normalized using the composite lowess method
(Yauk et al., 2006). Differentially expressed genes between dose
groups and controls were identiﬁed using the MAANOVA library.
The Fs statistic (Cui et al., 2005), a shrinkage estimator, was used
for the gene-speciﬁc variance components and the associated
p-values for all the statistical tests were estimated using the per-
mutation method (30,000 permutations with residual shufﬂing).
The p-values were then adjusted for multiple comparisons by using
the false discovery rate approach (FDR) (Benjamini and Hochberg,
1995). The least-squares means (Searle et al., 1980, Goodnight and
Harvey, 1978) were used to estimate the fold changes for each
pairwise comparison.
Gene set analysis was conducted using a rank based test (Alvo
et al., 2010) in R. Here, the relative expression for the genes in a
set or pathway is ﬁrst aligned by subtracting the median expres-
sion value for the combined treatment and control groups. These
values are then ranked within each RNA sample and the vector
of average ranks is calculated for each treatment group. The dis-
tance between the two treatments is calculated and a permutation
analysis is used to obtain a p-value for each gene set.
2.4. Benchmark dose calculations
BMDS 2.2 (U.S. EPA – http://www.epa.gov/ncea/bmds/in-
dex.html) and BENCH_C (Crump and Van Landingham, 1996) soft-
ware were used to calculate benchmark doses (BMD and BMDL).
Data for each gene set across IPR doses were derived from the
cumulative differences in expression of the genes within the set,
compared to the control mean, as explained in the Results.3. Results
3.1. IPR dose–response analysis of gene-set expression in mouse liver
Sixteen synexpression groups and gene batteries were em-
ployed to compare the relative ability of a multivariate Rank Test
and a univariate statistical test to detect signiﬁcant changes to
mRNA expression at a single time point, 8 h, after gavage exposure
of mice to a dose series (250, 50, 5, 0.5 mg/kg) of IPR. The lowest
doses in this series were approximately 10-fold above the maxi-
mum recommended dosage of IPR when delivered by inhaler for
relief of asthma symptoms in humans (Zheng et al., 2011).
It was expected that the multivariate Rank Test would provide
high sensitivity for low-dose changes in expression within certain
gene sets because of its accounting for co-ordinated expression
changes. The sixteen target gene sets were chosen to examine
IPR-induced, co-regulated behaviours dependent upon speciﬁc
transcription factors and post-transcriptional mechanisms likely
to be affected by diverse sources of tissue stress (p53, UPR, Nrf2,
Nfkb). Speciﬁc effects due to activation of beta-adrenergic recep-
tors by catecholamines were also considered since resultant rises
in cAMP levels induce Creb1 and Stat3 activities (Altarejos and
Montminy, 2011; Yu et al., 2009). Acute phase, and angiogenesissynexpression groups were included because several individual
gene members were identiﬁed as being signiﬁcantly affected in
the previous analysis of the data (Zheng et al., 2011). Expression
of genes within these two synexpression groups are controlled,
in part, by sets of transcription factors: acute phase by NF-jB
and STAT3 (also known as acute phase response factor) and others
(Quinton et al., 2009; Young et al., 2008), angiogenesis by Hif-alpha
and Id1 and others (Semenza, 2003; Watabe, 2011). Several addi-
tional gene sets were included for analysis because, at the outset
of this analysis, they were considered less likely to be affected by
IPR at low doses (e.g., PPAR, Fox_Smad, Ahr, Car, PxR, Srebp1,
50Top) and would serve as a comparative group for the highly
responding sets.
The multivariate analysis using the Rank Test indicated four-
teen of the sixteen gene sets to be signiﬁcantly affected by treat-
ment at the highest dose (250 mg/kg), compared to treatment
with vehicle alone. (Table 1).
Five gene sets (acute phase, angiogenesis, 50TOP, Stat3, Nfkb)
were shown to be signiﬁcantly affected, compared to controls,
across all four IPR doses using the multivariate Rank Test, with
an exception at a single dose. The 47-member Nfkb gene at the
5 mg/kg dose was not signiﬁcantly different (p < 0.22), although a
more restricted, preliminary list of 17 Nfkb-regulated genes was
considered to be signiﬁcantly affected (p < 0.02) at this dose (not
shown).
As indicated above, signiﬁcant expression changes in 50TOP
gene set were calculated by the Rank Test across the 500-fold
range of the four IPR doses. The mean relative expression ratios
(dose/vehicle), plotted in Fig. 1, reveal that all IPR doses depressed
the expression of most genes within this gene set. Overall, 43/92
measures (23 Top5 mRNAs present on ToxArray with 4 isoprotere-
nol doses = 92) were decreased by values between 1.25- and 1.5-
fold (when calculated as least square means- as in Zheng et al.,
2011). Changes of lesser magnitude were also predominantly
reductions. Six genes in the set (6/23; 0.26) were signiﬁcantly
changed by MAANOVA Fs analysis at the two top doses (250 and
50 mg/kg), while a single gene (Npm1, nucleophosmin) was also
signiﬁcantly affected at the 100-fold lower dose of 0.5 mg/kg. The
multivariate Rank Test, therefore was able to consistently discern
a slight, coordinated down-turn in the expression of the members
of the 50TOP gene battery at much lower concentrations than the
univariate test.
The relative expression ratios for the acute phase synexpression
group (Fig. 1) show that only the two highest doses of IPR (250 and
50 mg/kg) were able to signiﬁcantly change expression of a minor-
ity of the individual genes, according to the MAANOVA Fs test. In
contrast, the multivariate test indicated signiﬁcant IPR-induced ef-
fects at all doses down to the lowest dose (0.5 mg /kg), a 100 fold
lower concentration than was indicated by MAANOVA Fs test
(Table 1).
For the Nrf2 gene battery (Fig. 1), the highest dose (250 mg/kg)
of IPR produced six individual gene expression changes and the
next lower dose (50 mg/kg) induced a single gene (Mt-1) that
was signiﬁcant relative to control according to the MAANOVA Fs
test. The multivariate Rank Test indicated that the 50 mg/kg dose
also signiﬁcantly affected expression of the gene set (Table 1).
The relative expression results show that both increased expres-
sion (genes toward the left in the ﬁgure) and decreased expression
(genes to the right in the ﬁgure) were produced by IPR treatment at
these two doses.
Although most gene sets were determined to have signiﬁcant
treatment effects at the higher two doses according to the multi-
variate Rank Test, the Ahr and Foxo/Smad gene sets were not af-
fected by treatment at any IPR dose, while the Car gene set was
signiﬁcantly changed only at the highest dose (Table 1).
Table 1
Comparison of the multivariate Rank Test, and the univariate Maanova Fs statistic for ability to detect IPR-induced changes within synexpression groups and gene batteries in
murine liver.
A Multivariate rank test, p-value
Gene set id. # Probes 250 mg/kg vs control 50 mg/kg vs control 5 mg/kg vs control 0.5 mg/kg vs control
Acute phase 40 0.0079 0.0072 0.0316 0.0279
Angiogenesis 69 0.0145 0.0474 0.0238 0.0279
Ahr 7 0.2911 0.1655 0.2917 0.6038
Car 9 0.0444 0.7671 0.4264 0.3449
PXR 16 0.0222 0.1527 0.7654 0.1397
Fox Smad 5 0.0718 0.5221 0.9421 0.9092
50 Top 23 0.0149 0.0172 0.0436 0.0279
PPAR 20 0.0239 0.1740 0.1654 0.0558
Stat3 gene battery 42 0.0079 0.0072 0.0217 0.0279
NF kB TfactS gene battery 47 0.0079 0.0156 0.2507 0.0279
p53 TfactS 58 0.0079 0.1560 0.1323 0.2569
Unfolded protein response 11 0.0222 0.1230 0.4591 0.0857
SREBP1 gene battery 27 0.0079 0.0172 0.5989 0.2309
HIF 1alpha 34 0.0156 0.0794 0.1716 0.1452
Nrf2 extended 21 0.0079 0.0072 0.4670 0.0866
Creb1 TfactS 55 0.0079 0.1781 0.1252 0.2256
TOTAL: gene sets with signif. change 14 7 4 5
B Univariate maanova Fs, % tests signiﬁcant
Gene set id. # Probes 250 mg/kg vs control 50 mg/kg vs control 5 mg/kg vs control 0.5 mg/kg vs control
Acute phase 40 0.28 0.18 0.00 0.00
Angiogenesis 69 0.14 0.06 0.00 0.01
Ahr 7 0.00 0.00 0.00 0.00
Car 9 0.00 0.00 0.00 0.00
PXR 16 0.06 0.00 0.00 0.00
Fox Smad 5 0.00 0.00 0.00 0.00
5’Top 23 0.26 0.26 0.00 0.04
PPAR 20 0.10 0.05 0.00 0.00
Stat3 gene battery 42 0.21 0.07 0.00 0.00
NF kB TfactS gene battery 47 0.11 0.04 0.00 0.00
p53 TfactS 58 0.10 0.00 0.00 0.00
Unfolded protein response 11 0.18 0.00 0.00 0.00
SREBP1 gene battery 27 0.11 0.04 0.00 0.00
HIF 1alpha 34 0.09 0.06 0.00 0.00
Nrf2 extended 21 0.33 0.05 0.00 0.00
Creb1 TfactS 55 0.00 0.00 0.00 0.00
TOTAL: gene sets with signif. changea 12 9 0 2
a The univariate test, total sets with at least one individual gene signiﬁcant. Data extracted from (Zheng et al., 2011).
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Independent conﬁrmation of IPR effects on gene expression was
sought through direct comparison of the present microarray study
with other published data; however, no other published toxicoge-
nomic studies of the liver, in mice treated with IPR in vivo, were
discovered. In the rat heart, single subcutaneous administration
of IPR in the 0.008–0.5 mg/kg range has been studied as a cardio-
toxicity model, with doses below 0.064 mg/kg considered to pro-
duce potentially reversible histochemical changes (Zhang et al.,
2008). Two toxicogenomic studies bracketing the toxicity range
have been conducted with this cardiotoxicity model, although with
groups of only 3–5 animals (Mikaelian et al., 2008; Mori et al.,
2010). In a lower-dose study by Mori et al., histological analysis
revealed low levels of necrosis and inﬂammatory inﬁltration 8
and 24 h after a 0.01 mg/kg s.c. dose. In a higher-dose study by
Mikaelian et al., 0.5 mg/kg s.c. at multiple time points over 72 h
produced high levels of necrosis, inﬂammatory inﬁltration, and
some mortality.
The Rat Genome 230 2.0 (Affymetrix) microarray gene list
examined in these two rat cardiotoxicity studies was ﬁltered for
the features belonging to each gene-set of the present mouse liver
study. The data showed that the selected gene-sets were greatly af-
fected when analysed by both multivariate and univariate statisti-
cal tests used for the ToxArray data in the present and prior murine
study (Tables 2 and 3). Consistent with the high degree of toxicity
manifested as cardiac tissue necrosis, the higher dose data con-
tained multiple gene sets with affected individual genes signiﬁcantin the univariate test (Table 2). According to the multivariate anal-
ysis, most gene sets were signiﬁcantly affected at 1, 3, 72 h but not
at 8 h. Car and PXR gene batteries were not signiﬁcant at 1 and 3 h
but became signiﬁcant at 8 and 72 h, while UPR and Nrf2 at lost
signiﬁcance at 72 h.
In the lower dose rat cardiotoxicity study by Mori et al., most
gene sets were signiﬁcantly affected at 8 h, according to the multi-
variate analysis, and like the earliest time in the higher dose group,
the effects on the CAR gene set were not signiﬁcant (Table 3). At
this lower IPR dose, the univariate test detected no individual rat
genes as signiﬁcantly affected, including among the ﬁve gene sets
affected at all doses in the liver data of the present mouse liver
study (acute phase, angiogenesis synexpression groups and the
50TOP, Stat3 and Nfkb gene batteries). Except for the unfolded pro-
tein response in the multivariate test, there was lack of signiﬁcant
effect at 24 h in this experiment. The minimal response at the later
time was consistent with the possibility that the single, low, IPR
dose produced reversible cardiotoxic effects in rats.
3.3. Benchmark dose analysis
Data from signiﬁcantly affected gene sets was examined to
determine if any were sufﬁciently robust for use in quantitative
risk assessment procedures. Accordant with a multivariate statisti-
cal analysis the array information from all genes in a co-regulated
set was aggregated as the metric for calculations of benchmark
dose values. It was reasoned that a sum of expression changes cal-
culated across a larger set of genes might be less variable, among
Acute Phase 5’TOP Nrf2
Ah2 + Car
Yellow diamonds indicate significant Fs in Zheng et al., 2011
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1.5 to 2
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0.8 to 0.666
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Fig. 1. IPR-induced transcriptional responses within the Acute phase synexprssion group, 50TOP and Nrf2 gene batteries. Average (n = 5) fold changes at each dose, relative to
the vehicle control group, for each gene within each gene set are shown as individual cells within a heat map. The vertical arrangements of individual genes within each heat
map are based on the numerical difference between the vehicle control group average and the 250 mg/kg dose group (highest to lowest: top to bottom). Yellow diamonds
within a map cell indicate signiﬁcant differences (p < 0.05) from controls according to Maanova Fs calculated previously (Zheng et al., 2011). The p-values below each column
are reproduced from the Rank Test results in Table 1. Two non-overlapping oligonucleotide sequences (designated Mt1 and Mt-1) from Mt-1 mRNA were independently
spotted on Toxarray.
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genes determined by microarray hybridization. A ‘cumulative
expression difference’ within a gene set was deﬁned as the sum
of the absolute, relative fold-difference from the mean of the vehi-
cle control group, calculated for each of the member genes in a set.
The cumulative differences for the genes within a set were deter-
mined for each animal in the experiment, including those in the
vehicle control group, and used to establish dose group means
and standard deviations for entry into BMDS2.2 software. Data
for the acute phase gene set is presented in Fig. 2A. Coefﬁcient of
variation ranged from 20% to 29% across the 5 dose groups, with
a 3.7-fold (370%) increase in mean cumulative difference at the
highest dose, compared to the vehicle control. Maximum induced
change was therefore at least 10-fold greater than the relative var-
iance of the control. The Nrf2 gene battery displayed similar data
characteristics (Fig. 2B), however the variance of the data for 50TOP
battery was much wider (36–84%), while the largest increase in the
cumulative difference was 200% (Fig. 2C).
Based upon this input data for the acute phase gene set, BMD
(and BMDL) values of 3.41 (1.60) mg/kg, respectively, were calcu-
lated by BMDS2.2 software, using a reference benchmark of 0.1 in-
crease in the mean, based on the background value (vehicle treated
controls). An Hill sigmoidal model was plotted, given that IPReffects are mediated by beta adrenergic receptors which display
cooperative ligand binding characteristics (Del Carmine et al.,
2004) (Fig. 3B) . For each of the four gene sets examined (acute
phase, Nrf2, Nfkb, 50TOP), the Hill model was given a global good-
ness-of-ﬁt P-value of greater than 0.25, which exceeds the sug-
gested minimum (P 0.1) for consideration as a model of the data
(Risk Assessment Forum, 2000). BMD (and BMDL) values for Nrf2
and Nfkb gene batteries were similarly calculated as 6.78 (1.81)
and 3.31 (0.64) mg/kg, respectively (Fig. 3A). The Hill plot for the
50TOP gene battery did not give an accurate prediction of the
BMD (>0.0001 mg/kg), due to the steep, supralinear shape of the
model curve in the region between the vehicle control and the low-
est IPR dose. The BMDL values, based on the mean data for acute
phase, Nrf2 and Nfkb gene sets, are 12–36-fold above the recom-
mended daily maximum doses for human exposure indicated ear-
lier (0.05 mg/kg, Section 3.1).
The aggregate data sets plotted in Fig. 3A–D could also be con-
sidered as quantal data, by converting the cumulative differences
calculated for each mouse to a dichotomous score (affected or
unaffected), based upon a chosen, upper-bound value above the
mean of the control dose group (Crump, 1995). Illustrated in
Fig. 4 are the quantal values for Nrf2, acute phase, Nfkb and 50Top
gene sets, where the individual RNA samples with values greater
Table 2
Comparison of multivariate rank test and univariate Fs statistic for ability to detect higher-dose IPR-induced changes within synexpression groups and gene batteries in rat heart.
Data is taken from Mikaelian et al. (n = 3 vehicle; n = 4–5 treated).
1 h:0.5 mg/kg/ml IPR treatment vs control # Probes Multivariate rank test Univariate Fs statistic
Gene set .id p-value % Tests sig.
Acute phase 40 0.0163 0.08
Angiogenesis 81 0.0163 0.10
Ahr 9 0.0349 0.11
Car 10 0.0891 0.10
PXR 20 0.1076 0.00
Fox Smad 14 0.0319 0.21
50 Top 26 0.0163 0.00
PPAR 25 0.0163 0.04
Stat3 gene battery 55 0.0163 0.16
NF kB TfactS gene battery 57 0.0163 0.16
p53 TfactS 81 0.0163 0.07
Unfolded protein response 16 0.0511 0.06
SREBP1 gene battery 38 0.0163 0.13
HIF 1alpha 47 0.0163 0.11
Nrf2 extended 22 0.0163 0.18
Creb1 TfactS 71 0.0163 0.13
3 h:0.5 mg/kg/ml IPR treatment vs control
Acute phase 40 0.0683 0.25
Angiogenesis 81 0.0683 0.31
Ahr 9 0.0683 0.33
Car 10 0.0683 0.20
PXR 20 0.1330 0.30
Fox Smad 14 0.0683 0.43
50 Top 26 0.0683 0.19
PPAR 25 0.0683 0.16
Stat3 gene battery 55 0.0683 0.45
NF kB TfactS gene battery 57 0.0683 0.33
p53 TfactS 81 0.0683 0.20
Unfolded protein response 16 0.0683 0.25
SREBP1 gene battery 38 0.0683 0.42
HIF 1alpha 47 0.0683 0.30
Nrf2 extended 22 0.0683 0.41
Creb1 TfactS 71 0.0683 0.31
24 h: 0.5 mg/kg/ml IPR treatment vs Control
Acute phase 40 0.0573 0.13
Angiogenesis 81 0.0573 0.33
Ahr 9 0.0573 0.22
Car 10 0.0270 0.20
PXR 20 0.0270 0.20
Fox Smad 14 0.0573 0.29
50 Top 26 0.0573 0.46
PPAR 25 0.0573 0.20
Stat3 gene battery 55 0.0573 0.22
NF kB TfactS gene battery 57 0.0573 0.25
p53 TfactS 81 0.0573 0.31
Unfolded protein response 16 0.0573 0.44
SREBP1 gene battery 38 0.0573 0.16
HIF 1alpha 47 0.0270 0.26
Nrf2 extended 22 0.0573 0.32
Creb1 TfactS 71 0.0573 0.20
72 h: 0.5 mg/kg/ml IPR treatment vs control
Acute.phase 40 0.0181 0.35
Angiogenesis 81 0.0181 0.30
Ahr 9 0.0351 0.33
Car 10 0.0339 0.40
PXR 20 0.0328 0.35
Fox Smad 14 0.0181 0.29
50 Top 26 0.0510 0.19
PPAR 25 0.1035 0.08
Stat3 gene battery 55 0.0339 0.24
NF kB TfactS gene battery 57 0.0181 0.28
p53 TfactS 81 0.0668 0.19
Unfolded protein response 16 0.1182 0.13
SREBP1 gene battery 38 0.0181 0.18
HIF 1alpha 47 0.0363 0.23
Nrf2 extended 22 0.1019 0.23
Creb1 TfactS 71 0.0181 0.15
⁄Fs analysis was performed using affymetrix feature ID, after averaging probes with the same gene symbol.
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Animals with cumulative differences above the 2 S.D. value are
considered to be the ‘affected’ proportion animals (2.275%, whichis half that portion under the normal curve beyond 2 S.D.). BMD
and BMDL values based on an excess risk of 10% of animals in
the abnormal range were computed using a Weibull model chosen
Table 3
Comparison of multivariate Rank Test and univariate Fs statistic to detect lower-dose IPR-induced changes within synexpression groups and gene batteries in rat heart. Data is
taken from Mori et al. (n = 3).
8 h: 0.01 mg/kg isoproterenol treatment vs. control
Gene set .id # Probes Multivariate rank test Univariate Fs statistic
p-Value % Tests sig.
Acute.phase 40 0.0261 0.00
Angiogenesis 81 0.0252 0.00
Ahr 9 0.0142 0.00
Car 10 0.0747 0.00
PXR 20 0.0252 0.00
Fox Smad 14 0.0142 0.00
50 Top 26 0.0252 0.00
PPAR 25 0.0252 0.00
Stat3 gene battery 55 0.0252 0.00
NF kB TfactS gene battery 57 0.0142 0.00
p53 TfactS 81 0.0252 0.00
Unfolded protein response 16 0.0600 0.00
SREBP1 gene battery 38 0.0359 0.00
HIF 1alpha 47 0.0142 0.00
Nrf2 extended 22 0.2027 0.00
Creb1 TfactS 71 0.0252 0.00
24 h: 0.01 mg/kg isoproterenol treatment vs. control
Acute.phase 40 1.0000 0.00
Angiogenesis 81 0.8743 0.00
Ahr 9 0.8335 0.00
Car 10 0.3867 0.00
PXR 20 0.6258 0.00
Fox Smad 14 0.1808 0.00
50 Top 26 0.9658 0.00
PPAR 25 0.2262 0.00
Stat3 gene battery 55 0.9307 0.00
NF kB TfactS gene battery 57 0.5973 0.00
p53 TfactS 81 0.8774 0.00
Unfolded protein response 16 0.0485 0.00
SREBP1 gene battery 38 0.4592 0.00
HIF 1alpha 47 0.8267 0.00
Nrf2 extended 22 0.6245 0.00
Creb1 TfactS 71 0.9869 0.00
⁄Fs analysis was performed using affymetrix feature ID, after averaging probes with the same gene symbol.
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(4.14), 44.62 (7.63) and 6250 (169.83) mg/kg were calculated for
acute phase, Nfkb, Nrf2 and 50TOP gene sets, respectively (not
shown). The benchmark values based on an increase to a speciﬁed
increased probability of 0.1 in the proportion of affected animals
were greater than those obtained from the continuous data and a
speciﬁed effect of 0.1, shown in Fig. 3. Part of the higher BMD val-
ues, may be due to inaccuracies in ﬁtting the model to the data, due
to violation of the statistical assumption of constant variance in
each data set, since greater variances were observed in the highest
IPR dose group.
4. Discussion
This re-analysis of IPR-induced changes hepatic gene expression
in mice was undertaken as an illustrative exercise designed to
draw advantage from the high sensitivity of a multivariate statisti-
cal analysis based upon gene sets. High sensitivity to effects at low
doses was expected among a list of pre-deﬁned gene sets com-
posed of transcripts with deﬁned regulatory mechanisms that lead
to coordinated expression behaviours. Although the gene sets cho-
sen for study do have relevance to toxic outcomes, the list was not
intended to provide comprehensive coverage of toxicologically-
relevant gene sets.
The current study differs from earlier multivariate analyses,
summarized in the Introduction, in that the focus was centered
on gene sets that were restricted, a priori, to genes predicted likely
to respond to certain regulatory mechanisms . Six of the sixteen
selected gene batteries are listed in the data base supplied withthe Tfacts tool (Essaghir et al., 2010) which contains lists of genes
for which substantial experimental evidence exists for direct
control by speciﬁc transcription factors, while the other lists
were assembled from various literature sources. In the earlier
referenced studies, analyses included wider ranging gene sets
obtained from publically available compendia, such as those in
the Molecular Signatures Database (MSigDB) (Subramanian et al.,
2005). Receptor-based pathways provided in molecular pathway
and ontology-directed databases typically also include genes
whose products form components of the entire signalling pathway,
including the signal itself (e.g., growth factor ligand), its recep-
tor(s), the proteins producing second messengers and other
structural components of a signal transduction pathway(s), one
or more transcription factors and cofactors, as well as the target
genes for the transcription factor(s). Therefore, when toxin-in-
duced gene expression changes are conﬁned to the target gene
component of the set, their relative contribution to the estimation
of statistical signiﬁcance of treatment effect may be muted by the
contribution of non-responsive pathway members – especially
when changes in the target group are fewer and of small magni-
tude. The insensitivity of many pathway-related gene sets has been
previously noted (Montaner et al., 2009), wherein it was deter-
mined that for half of the KEGG pathways and two thirds of the
GO categories, the member genes do not demonstrate coordinated
expression patterns above the level of chance when examined
across a wide range of biological conditions. Such apparently
unresponsive gene groupings would not likely be selectively
responsive to toxic exposures. In contrast to the enzymological
and molecular pathways or gene ontology classiﬁcations, a gene
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Fig. 2. Cumulative differences plots for the IPR ﬁve treatment groups C, D4, D3, D2, D1 (vehicle control, 0.5, 5, 50, 250 mg/kg, respectively). Bars represent the ‘cumulative
expression difference’ within a gene set, which was deﬁned as the sum of the absolute, relative fold-difference from the mean of the vehicle control group, calculated for each
of the member genes in a gene-set. CD, cumulative difference value; CV, coefﬁcient of variation (S.D./mean). , p values were calculated for one-tailed t-tests (decreased
cumulative differences relative to the control were not expected).
70 C. Parfett et al. / Regulatory Toxicology and Pharmacology 67 (2013) 63–74group such as the 40 transcripts in the acute phase set encodes a
diverse collection of protein products that participate in a host of
molecular pathways. Similarly, individual transcription factors
such as Nfkb and Stat3 affect expression of wide collections ofgenes and thereby alter speciﬁc activities in multiple pathways
and biological processes. Since gene battery and synexpression
group classiﬁcations characteristically display coordinated expres-
sion changes during biologic or toxic events, it was reasonable to
Fig. 3. Plots of cumulative expression differences by BMDS2.2 software, using a
reference benchmark of 0.1 based on the mean background value (vehicle-treated
controls) and an Hill sigmoidal model through mean values at each dose. BMD,
benchmark dose.
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based upon both ranks of means and correlations among the indi-
vidual gene responses within each gene set.
The signiﬁcant calls for ﬁve gene groups (Nfkb, Stat3 and 50 ter-
minal oligopryrimidine [50TOP] gene batteries as well as the acute
phase and angiogenesis synexpression groups) were made at the
lowest two doses by the multivariate statistic. In comparison, onlytwo genes in these ﬁve sets, Npm1 and Idb1 in the 50TOP and angi-
ogenesis gene sets, respectively, were considered individually sig-
niﬁcant at the lowest two doses in our previous analysis (Zheng
et al., 2011). Signiﬁcance in the multivariate analysis was depen-
dent upon a coordinated series of many 1.25–1.5-fold inductions
or repressions within each gene group. The consistent detection
of these ﬁve gene sets, across all four dose levels, provided a vali-
dation of the reproducibility of multivariate approach to detect
small changes in expression within co-regulated gene sets. In gene
sets that were not signiﬁcantly affected at all doses, such as Nrf2,
the measure of signiﬁcance was greatest at the highest doses, as
would be expected. Further conﬁrmation of the high sensitivity
of the multivariate approach was provided by the similar effects
detected among these gene sets using the data from a cardiotoxic-
ity study in rats at a low, minimally toxic IPR dose.
In addition to the improved statistical performance provided by
testing gene batteries and synexpression groups in chemical dose–
response analysis, the particular changes induced within such
gene-sets provide insights into toxicological relevance of the ef-
fects. Much documentation and some experimental conﬁrmation
points to transcription factors such as Nfkb, Stat3 and Nrf2 playing
important roles in liver health and pathological events, depending
on cell speciﬁcity and source of insult (Robinson and Mann, 2010;
Sykiotis and Bohmann, 2010; Wang et al., 2011). The directions
and magnitudes of altered expressions within these gene-sets
could be interpreted as either toxic responses or as adaptive and
hormetic responses that serve to protect cells and tissues from lim-
ited exposures to stressful agents or conditions. Alternatively, dis-
ordered expression within gene-sets may be maladaptive or
dysregulated responses, also with potential for toxicity. It has also
been suggested that persistent, repeated activation of some stress
response pathways, as might occur during long-term exposure to
low-dose xenobiotics, could generate adverse side-effects, either
during critical periods of embryonic development or in mature
animals (Simmons et al., 2009; Barouki, 2010). In long-term expo-
sure settings, repeatedly triggered stress response pathways may
disrupt endogenous metabolism or generate cross-talk with other
signalling pathways, thereby playing causal roles in chronic
toxicities, according to tissue type and synergies with other
stressors such as age (Hotamisligil, 2010; Zhang et al., 2010;
Kourtis and Tavernarakis, 2011). Additional information support-
ing the likelihood of adverse outcomes resulting from the observed
changes in the acute phase, 50TOP and Nrf2 gene sets is presented
in a Supplemental Discussion ﬁle.
Applying toxicogenomic data to dose–response analysis in
health risk assessments remains a major challenge for regulatory
toxicology. One part of the challenge is to deﬁne and compile
acceptable evidence to support the contention that expression
changes in individual genes or in gene batteries and synexpression
groups are either associated indicators or are part of causal mech-
anisms that generate adverse outcomes. Although more work
needs to be done in this area, the discussion above and the
Supplemental Discussion ﬁle suggests the likelihood that
coordinated changes in gene expression within some gene sets
are connected to adverse apical events. A second challenge for
toxicogenomic information resides in the relative statistical insen-
sitivity of toxicogenomic data, due to small sample sizes and high
data dimensionality. The dose–response analysis conducted in the
present study indicated that applying cumulative expression dif-
ferences within a gene-set as a means to reduce dimensionality
and as a metric for deriving benchmark dose values was justiﬁed
by the relatively high low-dose sensitivity and acceptable data
quality associated with this metric. As judged by the CV values of
20–29% among the IPR doses groups, the hepatic gene expression
data compared favourably to the precision of clinical assays for cir-
culating acute phase reactants (CRP, SAA, ﬁbrinogen) which have
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Fig. 4. Scatter-column plots of ‘cumulative difference’ values for four gene sets, across the ﬁve IPR dose groups (n = 5 animals per group). The lower horizontal dashed line
plotted at the mean of the vehicle-treated control group. The upper horizontal dashed line plotted at the mean + 2 S.D. of the vehicle-treated control group. Values above or
below the upper horizontal line could be dichotomized to ‘affected’ or ‘unaffected’, respectively. Note, the X-axis is not to scale.
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greater variance of toxicogenomic data in the present study results
from both interassay (technical) variability and animal-to-animal
(biological) variability. Benchmark values calculated for gene-set
responses with acceptably low variances could serve as points of
departure in quantitative risk assessment procedures, adjusted
by appropriate uncertainty factors in order to derive a suitable ref-
erence dose (RfD) for human exposure. As is the case for classical
toxicological endpoints, gene expression measures harbour uncer-
tainties related to duration of toxin exposure, interspecies compar-
isons, and interindividual pharmacokinetic and pharmacodynamic
inﬂuences. In applying gene-set cumulative difference values to
benchmark dose estimates and in assessment of health risks, it
may be necessary to account for some additional uncertainty
around the choice of a relative amount of change from control lev-
els of the target genes (0.1 in the gene sets BMD calculations made
here) that could be considered adverse. Consideration of a ‘target
effect level’ has been suggested (Chiu et al., 2012) in relation to
the signal-to-noise crossover dose (Sand et al., 2011), which is a
newer strategy for point of departure derivation.
Analogous to the cumulative expression differences within gene
sets, composite indexes of aggregated data from batteries of tradi-
tional biochemical or functional tests targeted to measure related
domains of toxicity have been explored as an evaluative tool in ani-
mal toxicological studies on developmental and neurotoxic effects
(Coffey et al., 2007; Committee on the Health Risks of Phthalates,
2008; Moser, 1991). These aggregative approaches reduce data
dimensionality relative to the total of individual measures of ad-
verse outcome and avoid possible random effects in single end-
points or selection of only the most sensitive animal endpoint in
evaluating human health risk. Moreover, data aggregation fromsigniﬁcantly affected synexpression groups or gene batteries per-
mits more of the data obtained from the array to be used in a con-
ﬁdent manner. We are unaware of closely similar attempts to
evaluate and employ cumulative toxicogenomic data obtained
from co-regulated gene groups for the purpose of characterizing
dose–response relationships in animal toxicological studies; how-
ever, median BMD values of individually signiﬁcant genes within
broader pathway gene sets have been calculated (Black et al.,
2012).
In our previous analysis of this IPR dose–response experiment,
using an univariate parametric statistical tool (Fs statistic), we sug-
gested that points of departure for risk assessment could be based
on ‘No Adverse Transcriptional Effect Levels’ or ‘Lowest Adverse
Transcriptional Effect Levels’ (NOATEL/LOATEL), determined by a
select number of individual genes with signiﬁcant mRNA changes
and causal roles in toxicity. The selected mRNA responses dis-
played directions and magnitudes of change considered to be ad-
verse, as supported by experimental and other evidence in the
literature (Zheng et al., 2011). The present multivariate statistical
analysis of toxicologically-relevant gene batteries and synexpres-
sion groups extends the scope of this approach, in that statistically
signiﬁcant effects could be detected, in some cases, at doses much
lower than those showing signiﬁcant effects for individual target
genes. Although the multivariate analysis and use of aggregated
gene set responses provide an additional avenue of toxicogenomic
data analysis, it would be wise to also incorporate into the assess-
ment process any pertinent information gained from univariate
analyses or multivariate analyses based on molecular pathways
gene sets, particularly when evidence exists for causal linkages be-
tween mRNA expression changes and adverse physiological
outcomes.
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Re-analysis of a toxicogenomic dose–response study by means
of a multivariate statistical approach supported the conclusion that
an analysis centered on the responses of known toxin- and stress-
regulated gene batteries and synexpression groups can provide
high sensitivity at low doses. Closely co-regulated expression,
either uniform or discordant, induced within such gene sets can of-
ten be determined to be signiﬁcant without signiﬁcant expression
changes among the individual genes within a gene-set. Microarray-
based measurements of co-regulated gene-sets for which there is
evidence showing participation as key precursor events in adverse
outcomes, or for which there is strong evidence for association
with pathophysiological responses to toxins, may be applied to
benchmark dose calculations in quantitative health risk
assessments.
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